| From biology to treatment of monoclonal gammopathies of neurological significance A Visentin, S Pravato, F Castellani, M Campagnolo, F Angotzi, ... Cancers 14 (6), 1562, 2022 | 14 | 2022 |
| Four stages of hepatic hematopoiesis in human embryos and fetuses D Fanni, F Angotzi, F Lai, C Gerosa, G Senes, V Fanos, G Faa The Journal of Maternal-Fetal & Neonatal Medicine 31 (6), 701-707, 2018 | 14 | 2018 |
| Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study A Visentin, FR Mauro, G Catania, A Fresa, C Vitale, A Sanna, V Mattiello, ... Frontiers in Oncology 12, 1033413, 2022 | 9 | 2022 |
| Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies F Angotzi, M Petrella, T Berno, G Binotto, G Bonetto, A Branca, M Carraro, ... Frontiers in Oncology 13, 2023 | 6 | 2023 |
| A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody … A Visentin, MC Molinari, S Pravato, A Cellini, F Angotzi, CA Cavaretta, ... Current Oncology 30 (1), 274-283, 2022 | 6 | 2022 |
| Pre‐exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents. FR Mauro, A Visentin, D Giannarelli, MC Molinari, G Proietti, M Petrella, ... British Journal of Haematology 201 (3), 2023 | 5 | 2023 |
| Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells A Cellini, F Scarmozzino, F Angotzi, E Ruggeri, AP Dei Tos, L Trentin, ... Frontiers in Oncology 13, 1203470, 2023 | 3 | 2023 |
| Focal adhesion kinase activation by calcium‐dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness F Severin, N Mouawad, E Ruggeri, A Visentin, L Martinello, E Pagnin, ... British Journal of Haematology 203 (2), 224-236, 2023 | 2 | 2023 |
| Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study A Visentin, FR Mauro, L Scarfò, M Gentile, L Farina, G Reda, I Ferrarini, ... American Journal of Hematology 98 (9), E237-E240, 2023 | 2 | 2023 |
| Chronic lymphocytic leukemia (CLL) with borderline immunoglobulin heavy chain mutational status, a rare subgroup of CLL with variable disease course F Angotzi, A Cellini, V Ruocco, CA Cavarretta, I Zatta, A Serafin, S Pravato, ... Cancers 16 (6), 1095, 2024 | 1 | 2024 |
| Patients with Chronic Lymphocytic Leukemia Carrying t (14; 19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with … A Visentin, E Gaffo, M Furstenau, JA Woyach, P Baliakas, KA Rogers, ... Blood 142 (Supplement 1), 3275-3275, 2023 | 1 | 2023 |
| Serum Soluble Interleukin-2 Receptor Levels in Hairy Cell Leukemia As a Marker of Tumor Burden with Prognostic Value and As a Tool for Disease Monitoring F Angotzi, S Zoletto, A Cellini, C Cavaretta, V Ruocco, I Zatta, L Forlani, ... Blood 142, 4414, 2023 | 1 | 2023 |
| Multiple specialized stem cell niches characterize hematopoiesis in the human fetal liver D Fanni, F Angotzi, C Gerosa, D Barcellona, G Senes, F Lai, G Martino, ... Journal of Pediatric and Neonatal Individualized Medicine (JPNIM) 9 (1), e090118, 2020 | 1 | 2020 |
| Expression of CD34-positive progenitors in fetal human liver hematopoiesis D Fanni, F Angotzi, C Gerosa, F Lai, G Senes, P Van Eyken, V Fanos, ... VIRCHOWS ARCHIV 471 (S1), S144-S144, 2017 | 1 | 2017 |
| Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy E Ruggeri, F Frezzato, N Mouawad, M Pizzi, F Scarmozzino, G Capasso, ... Frontiers in Immunology 15, 1393485, 2024 | | 2024 |
| Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax‐based regimens A Serafin, A Cellini, CA Cavarretta, V Ruocco, F Angotzi, I Zatta, ... British Journal of Haematology, 2024 | | 2024 |
| Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience F Angotzi, F Lessi, M Leoncin, C Filì, M Endri, A Lico, A Visentin, ... Frontiers in Oncology 14, 2024 | | 2024 |
| P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS A Cellini, CA Cavarretta, F Angotzi, V Ruocco, A Serafin, I Zatta, ... HemaSphere 7 (S3), e132523d, 2023 | | 2023 |
| Andrea Visentin1, 2, Francesca Romana Mauro3, Gioachino Catania 4, Alberto Fresa5, Candida Vitale6, Alessandro Sanna7, Veronica Mattiello 8, Francesca Cibien9, Paolo … A Gozzetti15, S Molica16, M Marchetti, S Pravato, F Angotzi, A Cellini, ... Measurable residual disease in hematologic malignancies, 61, 2023 | | 2023 |
| P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study. A Visentin, A Cellini, CA Cavarretta, LR Gargarella, F Angotzi, V Ruocco, ... HemaSphere 6, 3, 2022 | | 2022 |
